DNDi R&D Portfolio June 2019

45 projects and more than 20 new chemical entities, with over 20 ongoing clinical trials

Download R&D portfolio & main partners – June 2019

Swipe left to see more
 

R&D discovery stage iconDISCOVERY

R&D translation stage iconTRANSLATION

R&D development stage iconDEVELOPMENT

R&D implementation stage iconIMPLEMENTATION

 
Screening
Hit-to-lead
Lead optimization
Pre-clinical
Phase I
Phase IIa/ Proof-of-concept
Phase IIb/III
Registration
Treatment access

Sleeping sickness

   


SCYX-1330682
SCYX-1608210

     


Acoziborole


Fexinidazole for T.b. rhodesiense

 


Fexinidazole for T.b. gambiense

Nifurtimox-eflornithine combination therapy (NECT)

Leishmaniasis

Screening

Leishmaniasis hit-to-lead

NTD Drug Discovery Booster hit-to-lead

Daiichi-Sankyo hit-to-lead


DNDI-5421
DNDI-5610


Aminopyrazoles

CF series

Leishmaniasis L205 series


DNDI-5561


GSK3494245
DDD1305143

CpG-D35
for CL


DNDI-6148


DNDI-0690


GSK3186899
DDD853651

 

New CL combination

New treatments for PKDL

Miltefosine + paromomycin combination (Africa)

New VL
treatments
(Latin America)

New treatments for HIV/VL

SSG&PM
(East Africa)

New VL treatments
(South Asia)

Chagas disease

Screening

Chagas hit-to-lead

NTD Drug Discovery Booster hit-to-lead

Daiichi-Sankyo hit-to-lead


Chagas
C205 series

Biomarkers

 


Fexinidazole


New benznidazole regimens

 

Benznidazole
paediatric
dosage forms

Filarial diseases

Screening

 


Macrofilaricide 3

 


Oxfendazole


Emodepside


TylAMac (ABBV-4083)

     

Mycetoma

           


Fosravuconazole

   

HIV

           

4-in-1
(ABC/3TC/
LPV/r)

 

Super-booster therapy
for children with HIV/TB

2-in-1 LPV/r pellets and ABC/3TC or AZT/3TC

Hepatitis C

           


Ravidasvir + sofosbuvir


Ravidasvir

 

Malaria

Implementation transferred to the Medicines for Malaria Venture in 2015
               

Fixed-dose combination ASAQ

Fixed-dose combination ASMQ

New Chemical Entity (NCE)

Completed Projects

Chagas access project